Activation of the TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ pediatric AML
L. Cifarelli, Hasan IssaiD, Ludovica ProiettiiD, K SchuscheliD, Lucie Gack, Katja Menge, Christian H. IhlingiD, Meike VogleriD, Andrea SinziD, Jan‐Henning KlusmanniD, Dirk HeckliD
Abstract
NUP98::KDM5A-rearranged pediatric acute myeloid leukemia (AML) is a rare, infancy-predominant entity with dismal outcome and no targeted therapeutic options. Given its suspected fetal origin, we hypothesized that leukemic maintenance depends on developmentally restricted vulnerabilities embedded within fetal hematopoietic programs. Using matched fetal and adult hematopoietic stem and progenitor cell models, we integrated transcriptomic and proteomic profiling with CRISPR-Cas9 screenings to define ontogeny-specific dependencies in NUP98::KDM5A leukemia. Fetal-derived NUP98::KDM5A leukemias exhibited greater in vivo aggressiveness, and retained fetal transcriptional signatures compared with adult counterparts. A comparative CRISPR-Cas9 screen using a library targeting fetal gene programs, conducted in both fetal- and adult-derived NUP98::KDM5A leukemias, identified the AAA ATPase TRIP13 as a selective and essential dependency in the fetal context. Mechanistically, TRIP13 physically interacted with the TP53 phosphatase PPM1D/WIP1, resulting in suppression of TP53 activation. Genetic ablation of Trip13, or pharmacologic inhibition using DCZ0415, a small-molecule inhibitor targeting TRIP13, reactivated TP53, induced G2/M arrest and mitochondrial apoptosis, and depleted leukemic cells in vitro; these effects were fully rescued by TP53 loss. In competitive transplantation assays, Trip13 ablation significantly impaired leukemic fitness in vivo. Together, these findings define a developmentally restricted TRIP13-PPM1D-TP53 survival axis in NUP98::KDM5A AML and provide mechanistic proof-of-concept that reactivation of the TP53 signaling pathway via TRIP13 inhibition represents a therapeutically targetable vulnerability in this high-risk pediatric leukemia. Visual abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=121 SRC="FIGDIR/small/675580v4_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@143d103org.highwire.dtl.DTLVardef@14f3225org.highwire.dtl.DTLVardef@655541org.highwire.dtl.DTLVardef@c021ae_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis
O. Alejo-Valle, K. Weigert, … J.-H. Klusmann·bioRxiv·Apr 26, 2021
- BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia
Ahmed M. Mamdouh, Fang Qi Lim, … Shruti Bhatt·bioRxiv·May 17, 2025
- TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade
Ahmed M. Mamdouh, Elyse A. Olesinski, … Shruti Bhatt·bioRxiv·Aug 28, 2025
- Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemia
R. R. Posey, J. D. Lee, … P. P. Pandolfi·bioRxiv·Mar 22, 2020
- STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in TP53-mutated AML
Kaushlendra K. Tripathi, Lora Stojanovic, … Feyruz Virgilia Rassool·bioRxiv·Jul 28, 2026
- Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma
D. Pölöske, H. Sorger, … R. Moriggl·bioRxiv·Oct 12, 2023